TMCI LAWSUIT ALERT: Levi & Korsinsky Notifies Treace Medical Concepts, Inc. Investors – Lead Plaintiff Deadline June 10, 2025
Levi & Korsinsky LLP has announced a class action securities lawsuit against Treace Medical Concepts, Inc. (NASDAQ: TMCI) for alleged securities fraud between May 8, 2023, and May 7, 2024. The lawsuit claims that the company made false statements and/or concealed that competition impacted demand for its "Lapiplasty" product, leading to revenue decline and the need for alternative products. Investors who suffered losses during this period are encouraged to learn about their rights to seek recovery, with a lead plaintiff deadline of June 10, 2025.
TMCI - Treace Medical Concepts Inc Volatility & Greeks
This article provides a detailed financial overview of Treace Medical Concepts Inc (TMCI), including its stock performance, key financial metrics, volatility data, and institutional/insider ownership. It covers various ratios, growth rates, and analyst recommendations, offering a snapshot of the company's current market position.
TMCI - Treace Medical Concepts Inc Earnings
This article provides a detailed financial overview of Treace Medical Concepts Inc (TMCI), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider and institutional ownership, and short interest data, along with analyst recommendations and price targets.
Treace Medical Concepts, Inc.(NasdaqGS:TMCI) dropped from Russell Small Cap Comp Growth Benchmark
Treace Medical Concepts, Inc. (TMCI) has been removed from the Russell Small Cap Comp Growth Benchmark, as well as several other Russell indices including the Russell 2500 Growth Benchmark, Russell 2000 Index, Russell 2500 Index, and Russell 3000 Index. Concurrently, the company was added to the Russell Microcap Growth Benchmark Index and the Russell Microcap Index. This rebalancing reflects changes in the company's market capitalization and growth profile.
Treace Medical Concepts, Inc. (TMCI) Investigation: Bronstein, Ge
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Treace Medical Concepts, Inc. (NASDAQ: TMCI). The firm encourages investors who purchased Treace Medical securities before May 8, 2023, and still hold them, to contact them to learn more and assist the investigation. The representation of investors is on a contingency fee basis.
Levi & Korsinsky Notifies Treace Medical Concepts, Inc. (TMCI) Investors - Lead Plaintiff Deadline on June 10, 2025
Levi & Korsinsky has announced a lead plaintiff deadline of June 10, 2025, for investors of Treace Medical Concepts, Inc. (TMCI) who suffered losses due to alleged securities fraud. The class action lawsuit claims the company made false statements about competition impacting demand for its main product, leading to revenue decline and the need for alternative products. Investors who purchased TMCI stock between May 8, 2023, and May 7, 2024, are encouraged to learn about their rights.
Price to earnings forward of Treace Medical Concepts, Inc. – NASDAQ:TMCI
This article briefly presents the "Price to earnings forward" value for Treace Medical Concepts, Inc. (NASDAQ: TMCI). The content, likely from a financial data platform, shows the value for a specific period without providing further details or analysis.
Analysts Are Updating Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Estimates After Its First-Quarter Results
This article states that analysts are updating their estimates for Treace Medical Concepts, Inc. (NASDAQ:TMCI) following the release of its first-quarter results. The content is missing, preventing a detailed summary of the company's performance or analyst reactions.
Enterprise value to revenue forward of Treace Medical Concepts, Inc. – NASDAQ:TMCI
The article provides the enterprise value to revenue forward for Treace Medical Concepts, Inc. (NASDAQ: TMCI). It lists the current value, change, and percentage change for this financial metric. The content appears to be a snapshot from a financial data platform, likely TradingView, focusing solely on this specific financial ratio for the company.
Price to earnings forward of Treace Medical Concepts, Inc. – BOATS:TMCI
This page from TradingView displays the "price to earnings forward" metric for Treace Medical Concepts, Inc. (TMCI) under its Blue Ocean Alternative Trade System (BOATS) listing. It appears to be a financial data point for the company, accessible within a broader financial and market analysis platform. The content is primarily a navigation path and a placeholder for the specific financial data.
Enterprise value to EBITDA forward of Treace Medical Concepts, Inc. – NASDAQ:TMCI
This article provides financial information for Treace Medical Concepts, Inc. (NASDAQ: TMCI), specifically focusing on its enterprise value to forward EBITDA. The content appears to be a stub or an incomplete data presentation page from TradingView, indicating financial metrics without providing the actual values.
Treace Medical Concepts Inc (TMCI) Institutional Confidence
The article analyzes the institutional confidence in Treace Medical Concepts Inc (TMCI), noting its current institutional shareholding score of 5.00, placing it 109th out of 204 in the Healthcare Equipment & Supplies industry. It highlights that the latest institutional shareholding proportion is 58.61%, a 4.20% decrease quarter-over-quarter, with James Simons being the largest institutional shareholder despite a recent increase in his holdings. The article also provides a detailed list of major institutional shareholders and their changes in shareholdings.
Treace Medical Concepts (TMCI) Sidoti Small-Cap Virtual Investor Conference Summary
This article summarizes Treace Medical Concepts' (TMCI) presentation at the Sidoti Small-Cap Virtual Investor Conference. Key takeaways include the company's strategic focus on 3D bunion correction, expansion into new product lines, and positive financial performance with improved adjusted EBITDA and reduced cash usage. TMCI plans to commercialize the next-generation Lapiplasty Lightning platform in late 2026 and aims for cash flow independence within the next one to two years.
Treace Medical Concepts (TMCI) Q3 2024 earnings summary
Treace Medical Concepts (TMCI) reported Q3 2024 revenue of $45.1 million, an 11% increase year-over-year, and a net loss of $15.4 million ($0.25 per share), an improvement from the prior year. The company launched the Nanoplasty 3D MIS system and is pursuing patent litigation. TMCI revised its full-year 2024 revenue guidance to $204–$211 million and aims for Adjusted EBITDA break-even in 2025.
Treace Medical Concepts (TMCI) Proxy filing Summary
Treace Medical Concepts (TMCI) released a summary of its proxy filing for the upcoming annual meeting on May 19, 2026. Key highlights from 2025 include the launch of new minimally invasive bunion correction systems, expansion into biologics, and $212.7 million in revenue. Shareholders will vote on director elections, executive compensation, and auditor ratification, with the board recommending approval for all proposals.
Treace Medical Concepts (TMCI) Q2 2024 earnings summary
Treace Medical Concepts (TMCI) reported Q2 2024 revenue of $44.5 million, marking a 6% year-over-year increase, driven by higher case volumes and new product adoption. Despite revenue growth, the company's net loss widened to $21.2 million due to increased operating expenses and strategic investments. TMCI reaffirmed its full-year 2024 revenue guidance of $201–$211 million and expects significant Adjusted EBITDA improvement, while continuing its expansion into the minimally invasive osteotomy market.
Treace Medical Concepts (TMCI) 2024 Truist Securities MedTech Conference Summary
Treace Medical Concepts (TMCI) presented at the 2024 Truist Securities MedTech Conference, highlighting market evolution, growth opportunities, and strategic responses to increased competition. The company plans to launch two minimally invasive osteotomy platforms by late 2024 to capture a larger share of the bunion surgery market, which has seen rivals introduce similar products. Despite a shift in surgeon behavior, TMCI aims to expand its product suite and reach new surgeon segments to drive future growth.
Treace Medical Concepts (TMCI) Sidoti Small-Cap Virtual Investor Conference Summary
Treace Medical Concepts (TMCI) presented at the Sidoti Small-Cap Virtual Investor Conference, highlighting its strategic focus on 3D bunion correction technologies and its significant market share in the U.S. bunion market. The company discussed its expanded product portfolio, including new Lapiplasty, Nanoplasty, and Percuplasty systems, and its upcoming Lapiplasty Lightning platform. TMCI also detailed its go-to-market strategy, emphasizing its direct sales force and medical education programs.
Treace treats its first patient with HyperPlate XM foot implant
Treace (Nasdaq: TMCI) has successfully completed the first surgical case using its new HyperPlate™ XM Dynamic Compression Locking Implant, an extension of its SpeedPlate platform for midfoot and hindfoot fusion procedures and osteotomies. The titanium system features FastPitch locking screws for rapid insertion and dynamic compression, complemented by single-use sterile instruments like the GreatReleaseXM™ Rapid Release Instrument. Full commercialization of the HyperPlate™ XM system is anticipated in the third quarter of 2026, aiming to broaden Treace's procedural reach and portfolio adoption in the foot and ankle market.
Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System
Treace Medical Concepts, Inc. announced the successful completion of the first surgical case using its new HyperPlate™ XM Dynamic Compression Locking Implant system. This system, designed for midfoot and hindfoot fusion procedures, offers enhanced stability and dynamic compression. Full commercialization of the HyperPlate™ XM implants and complementary instruments is expected in the third quarter of 2026.
Treace Medical Concepts Inc (TMCI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey
The article provides a snapshot of Treace Medical Concepts Inc. (TMCI) stock performance, showing a slight increase of 1.39%. It highlights the company's market capitalization but notes that relevant data regarding revenue breakdown by business segments and regions has not yet been disclosed by the company. The page appears to be a stub for financial data that is currently unavailable.
Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System
Treace Medical Concepts, Inc. announced the successful completion of the first surgical case using its new HyperPlate™ XM Dynamic Compression Locking Implant system. This new system, designed for midfoot and hindfoot fusions, combines locking screws and dynamic compression for enhanced stability. The company anticipates full commercialization of the HyperPlate™ XM system in the third quarter of 2026, aiming to expand its market reach and support a growing range of foot and ankle procedures.
Treace Medical Concepts Inc (TMCI) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Treace Medical Concepts Inc (TMCI), noting its current earnings forecast score is 6.00 and ranks 169 out of 203 in the Healthcare Equipment & Supplies industry. Analysts have a "Hold" rating on the stock with an average price target of $5.00. The company's expected revenue for the next quarter is $44.02 million, and its EPS for the next quarter is projected at USD -0.30.
Treace Medical Concepts Inc (TMCI) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Treace Medical Concepts Inc (TMCI), listing major individual and institutional investors. It provides a breakdown of shareholder types, institutional holdings over several recent quarters, and recent shareholder activities including changes in ownership percentages.
Treace Medical Concepts Inc (TMCI) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis of Treace Medical Concepts Inc (TMCI), noting its current valuation score of 8.19, which ranks it 109 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of -4.31, which is significantly below its recent high and above its recent low. However, relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Treace Medical Concepts CEO John T. Treace buys $99,195 in stock By Investing.com
John T. Treace, CEO of Treace Medical Concepts (NASDAQ: TMCI), recently purchased 24,606 shares of company common stock for a total of $99,195. These transactions occurred on June 10 and June 11, 2026, at weighted average prices between $4.024 and $4.0423 per share. Following these acquisitions, Mr. Treace directly holds over 7.3 million shares and also has significant indirect holdings through trusts.
Treace Medical Concepts CEO John T. Treace buys $99,195 in stock By Investing.com
Treace Medical Concepts CEO John T. Treace recently purchased $99,195 worth of company stock, acquiring shares across two days. These transactions, reported in an amended SEC filing, involved 24,606 shares at weighted average prices between $4.024 and $4.0423. Following these acquisitions, CEO John T. Treace directly holds over 7.3 million shares, and the company has shown positive financial results, beating analyst expectations for Q1 2026.
Treace Medical Concepts CEO John T. Treace buys $210,967 in stock
John T. Treace, CEO of Treace Medical Concepts (NASDAQ: TMCI), recently invested $210,967 in company stock through two separate purchases on June 10 and 11, 2026, acquiring a total of 52,317 shares. These transactions occurred amid strong stock performance, with the company’s shares returning 11.4% over the past week and 59.59% year-to-date. Treace's direct holdings now total 7,376,150 shares, and the company also recently reported Q1 2026 financial results that exceeded analyst expectations for both EPS and revenue.
Treace Medical (TMCI) CEO boosts direct stake with June share buys
Treace Medical Concepts CEO John T. Treace increased his direct stake in the company by purchasing 24,606 shares in June, correcting a previous reporting error. These open-market transactions on June 10th and 11th were executed at weighted average prices of $4.0240 and $4.0423 respectively. Following these buys, Treace directly holds 7,348,439 common shares and also reports indirect holdings through various trusts and his spouse.
Treace Medical Concepts CEO John T. Treace buys $99,195 in stock
John T. Treace, CEO of Treace Medical Concepts (NASDAQ:TMCI), recently purchased $99,195 worth of company stock through two transactions on June 10 and 11, 2026. These acquisitions increased his direct holdings to over 7.3 million shares and reflect a positive outlook, as the stock has seen an 11% gain in the past week and a 60% year-to-date return. The company also reported better-than-expected Q1 2026 financial results, and analysts view the stock as undervalued with "GOOD" financial health despite current unprofitability.
Treace Medical Concepts CEO John T. Treace buys $210,967 in stock
John T. Treace, CEO of Treace Medical Concepts (NASDAQ:TMCI), recently purchased shares worth $210,967 in two separate transactions on June 10 and 11, 2026, acquiring a total of 52,317 shares. These purchases occurred during a period of strong stock performance, with the company also announcing positive Q1 2026 financial results that exceeded analyst expectations and the election of new Class II directors. Mr. Treace now directly holds over 7.3 million shares and has indirect ownership through various trusts and his spouse.
Treace Medical (NASDAQ: TMCI) CEO adds 52,317 shares in open-market purchases
John T. Treace, CEO of Treace Medical Concepts (NASDAQ: TMCI), reported open-market purchases of 52,317 common shares. These transactions, valued at approximately $211,000, occurred on June 10th and 11th, increasing his direct stake to 7,376,150 shares, including restricted stock units. The purchases signal a positive yet incremental increase in his holdings rather than a major shift.
Treace to Present at the Sidoti Small Cap Conference
Treace Medical Concepts, Inc. announced it will present at the Sidoti Small Cap Conference on Thursday, June 18, 2026, at approximately 1:45 pm ET. A live webcast and replay of the presentation will be available on the company's investors relations website. Treace is a medical technology company focused on surgical treatments for bunions and related midfoot deformities, including its Lapiplasty® 3D Bunion Correction® System.
Treace to Present at the Sidoti Small Cap Conference
Treace Medical Concepts, Inc. announced it will present at the Sidoti Small Cap Conference on Thursday, June 18, 2026, at 1:45 pm ET. A webcast of the presentation will be available on the company’s investor relations website. Treace is a medical technology company focused on advancing surgical treatments for bunions and related midfoot deformities.
Treace Medical CEO John Treace buys $177,915 in company stock
John T. Treace, CEO of Treace Medical Concepts, Inc. (NASDAQ:TMCI), recently purchased 50,000 shares of company stock for $177,915, following a significant rally in the stock's price. This transaction brings his direct holdings to over 7.3 million shares. The purchase comes after Treace Medical reported better-than-expected first-quarter 2026 financial results, with earnings and revenue surpassing analyst forecasts.
Treace Medical (TMCI) CEO buys 50,000 shares in open-market trade
Treace Medical Concepts CEO John T. Treace purchased 50,000 shares of common stock in an open-market transaction on June 1, 2026, at a weighted average price of $3.5583 per share. This transaction increases his direct holdings to 7,323,833 shares, including restricted stock units. The filing also details indirect holdings through trusts and his spouse, though Treace disclaims beneficial ownership of these indirect shares.
Treace Medical (NASDAQ:TMCI) CEO John Treace acquires $340,588 in shares
Treace Medical (NASDAQ:TMCI) CEO John Treace recently acquired 115,520 shares of the company's common stock for a total of $340,588 through open-market purchases between May 26 and May 28, 2026. These transactions increased his direct holdings to over 7.2 million shares, with additional indirect holdings. This comes as the stock has shown an 18% gain year-to-date, despite the company not being profitable in the last twelve months, and follows a Q1 2026 financial report that surpassed analyst expectations for EPS and revenue.
Treace Medical Concepts (TMCI) CEO buys 115,520 shares of stock
John T. Trease, CEO of Treace Medical Concepts (TMCI), recently purchased 115,520 shares of common stock through open-market transactions on May 26, 27, and 28, 2026. These purchases, totaling approximately $340,589, increased his direct holdings to 7,273,833 shares, including restricted stock units. The CEO also holds indirect shares through trusts and his spouse, though he disclaims beneficial ownership of those.
William Blair Investment Management LLC Sells 2,488,883 Shares of Treace Medical Concepts, Inc. $TMCI
William Blair Investment Management LLC significantly reduced its stake in Treace Medical Concepts, Inc. (NASDAQ:TMCI) by 68.5% in the fourth quarter, selling 2,488,883 shares. Despite this, insider buying activity continued, with CEO John T. Treace acquiring additional shares. Treace Medical Concepts reported a smaller-than-expected loss and stronger revenue, though analysts largely maintain a "Reduce" rating for the stock.
Treace Medical Shareholders Back Directors, Pay and Auditor
At its annual meeting, Treace Medical Concepts shareholders re-elected three Class II directors for three-year terms, signaling continued support for the company's current board and strategic direction. Investors also approved the executive compensation program and ratified Grant Thornton LLP as the independent auditor, ensuring continuity in financial oversight. An analyst rating on TMCI stock is a Hold with a $2.00 price target, while TipRanks’ AI Analyst, Spark, rates it Neutral due to weak financial performance despite strong gross margins.
Treace Medical Concepts shareholders elect directors and approve key proposals
Treace Medical Concepts Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected Lance A. Berry, Elizabeth S. Hanna, and Jane E. Kiernan as Class II directors. They also approved the compensation for executive officers and ratified Grant Thornton LLP as the independent accounting firm for fiscal year 2026. The company recently reported better-than-expected Q1 2026 financial results, with shares gaining 11% in the past week and 15% year-to-date.
Treace Medical (TMCI) shareholders elect directors and ratify auditor at 2026 meeting
Treace Medical Concepts, Inc. (TMCI) stockholders elected three Class II directors, Lance A. Berry, Elizabeth S. Hanna, and Jane E. Kiernan, to serve three-year terms expiring at the 2029 annual meeting. Shareholders also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The decisions were made at the company's 2026 annual meeting held on May 19, 2026.
TMCI SEC Filings - Treace Medical Concepts, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders to access official regulatory documents for Treace Medical Concepts (TMCI), including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. Recent filings detail beneficial ownership by Armistice Capital and Steven Boyd, as well as insider transactions for several company officers, including the CFO, C. Legal & Compliance Officer, Chief Innovation Officer, and SVP of Sales. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis for enhanced investor insight.
Treace Medical Concepts (TMCI) director awarded 30,000 RSUs
Treace Medical Concepts director Lance A. Berry was awarded 30,000 restricted stock units (RSUs) as an equity grant. These RSUs will vest 100% on the earlier of May 19, 2027, or the 2027 annual meeting of stockholders, provided he continues his service to the company. After this grant, Berry's direct holdings in Treace Medical Concepts total 74,593 shares, including the newly awarded RSUs.
Director at Treace Medical (TMCI) receives 30,000 restricted stock units
Deepti Jain, a director at Treace Medical Concepts (TMCI), has received a grant of 30,000 restricted stock units (RSUs) at no purchase price. These RSUs will vest 100% on the earlier of May 19, 2027, or the 2027 annual stockholders' meeting, contingent on her continued service. Following this transaction, Jain's total holdings, including the RSUs, amount to 100,243 common shares.
Treace Medical (TMCI) awards 30,000 RSUs to company director
Treace Medical Concepts (TMCI) director Lawrence W. Hamilton was granted 30,000 restricted stock units (RSUs) as compensation, not via an open-market purchase. These RSUs will vest 100% on the earlier of May 19, 2027, or the 2027 annual meeting of stockholders, provided Hamilton remains with the company. He has elected to defer receiving the underlying shares until a change in control or his separation from service, bringing his total direct holdings to 74,056 shares.
Treace Medical Concepts (NasdaqGS:TMCI) Stock Forecast & Analyst Predictions
Treace Medical Concepts (TMCI) is projected to grow earnings by 7.6% and revenue by 5% annually, despite remaining unprofitable over the next three years. Analysts have frequently revised price targets downwards due to competitive pressures, product mix shifts, and slower growth expectations, alongside a securities class action lawsuit. The company is introducing new products like SuperBite Compression Screw System and SpeedXM Midfoot Fusion System to address a broader market, yet faces ongoing financial challenges and stock volatility.
Armistice Capital (TMCI) discloses 6.36M shares, 9.85% stake
Armistice Capital, LLC and Steven Boyd have reported a 9.85% beneficial ownership stake in Treace Medical Concepts, Inc. (TMCI), totaling 6,364,000 shares of common stock. This disclosure was made via a Schedule 13G/A amendment, indicating that Armistice Capital, as the investment manager for Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these shares. The filing clarifies the reporting persons and their responsibilities under an Investment Management Agreement, explicitly disclaiming direct beneficial ownership for the Master Fund due to its inability to vote or dispose of the securities directly.
Treace Medical Concepts Insider Bought Shares Worth $375,505, According to a Recent SEC Filing
This article reports on an insider purchase of Treace Medical Concepts shares. An insider recently bought shares worth $375,505, as disclosed in a recent SEC filing.
Treace Medical Concepts CEO John Treace buys $375,505 in shares By Investing.com
John T. Treace, CEO of Treace Medical Concepts (NASDAQ: TMCI), recently purchased approximately $375,505 worth of the company's common stock over three days in mid-May 2026. These purchases occurred at prices between $2.1739 and $2.6153 per share, preceding a significant stock rally. The CEO now directly holds over 7.15 million shares, and the company also reported better-than-expected Q1 2026 earnings despite a revenue decline.
